A subset of CD45+/CD19 - cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma.
Mantle cell lymphoma has features of both indolent and aggressive non-Hodgkin lymphomas. Repeated relapses leading to treatment failure in patients with mantle cell lymphoma might suggest the presence of cancer stem cells. A small cell population with CD45+/CD19 - was previously reported to represent cancer stem cells. We evaluated the clinical relevance of CD45+/CD19 - cells in bone marrow of patients with mantle cell lymphoma (n = 20). A CD45+/CD19 - cell population was observed in newly diagnosed mantle cell lymphoma, and its percentage correlated with tumor cells in bone marrow (r = 0.832, p = 0.001) and score on the simplified mantle cell lymphoma prognostic index (r = 0.675, p = 0.016). After treatment, CD45+/CD19 - cells decreased (mean: 0.012%), and CD45+/CD19 - cells (0.276%) were higher at relapse or progression than at diagnosis. In conclusion, a CD45+/CD19 - cell population in bone marrow aspirates correlated with the clinical outcome of patients with mantle cell lymphoma.
a Division of Hematology-Oncology, Department of Medicine , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea.
Sung Min
SM
Kim
b Department of Laboratory Medicine and Genetics , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea.|f Department of Laboratory Medicine , Yonsei University College of Medicine , Seoul , Korea.
Seung-Tae
ST
Lee
c Samsung Biomedical Research Institute, Research Institute for Future Medicine, Samsung Medical Center , Seoul , Korea.
Kyung Ju
KJ
Ryu
b Department of Laboratory Medicine and Genetics , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea.
Hee-Jin
HJ
Kim
b Department of Laboratory Medicine and Genetics , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea.
Sun-Hee
SH
Kim
d Department of Pathology , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea.
Young Hye
YH
Ko
a Division of Hematology-Oncology, Department of Medicine , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea.
Won Seog
WS
Kim
a Division of Hematology-Oncology, Department of Medicine , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea.|e Department of Medical Device Management and Research , Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University , Seoul , Korea.
Seok Jin
SJ
Kim
D000368:Aged; D018941:Antigens, CD19 / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D001854:Bone Marrow Cells / Q000378:metabolism* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D017493:Leukocyte Common Antigens / Q000378:metabolism*; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D016896:Treatment Outcome
D018941:Antigens, CD19; D015415:Biomarkers; D017493:Leukocyte Common Antigens
Cancer stem cell; bone marrow; mantle cell lymphoma